Scribe Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 17.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 330.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Details
| Name | Scribe Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 82 |
| Founded | 2017 |
| Ipo Date | 2026-07-24 |
| Ceo | Benjamin Oakes |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 15.00 |
| Isin | US8110331092 |
| Cusip | 811033109 |
| Cik | 1853921 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Benjamin L. Oakes Ph.D. | Co-Founder, President, Chief Executive Officer and Chairman |
| David L. Parrot M.B.A. | Chief Financial Officer and Treasurer |
| Dr. Svetlana Lucas Ph.D. | Chief Operating Officer |
| Dr. Jennifer A. Doudna Ph.D. | Co-Founder and Scientific Advisor |
| Brett T. Staahl Ph.D. | Co-Founder and Vice President of External Innovation |
| David F. Savage Ph.D. | Co-Founder and Scientific Advisor |
| Richard Hector J.D., Ph.D. | Head of Intellectual Property |
| Chitra Sharma M.S. | Senior Vice President of Development |
| Sunny Mok M.B.A., Ph.D. | Senior Vice President of Operations |
| Stephen V. Thau | Secretary |
Contact
| Address | 1150 Marina Village Pkwy, Alameda, California 94501, United States |
| Phone | 510 626 8587 |
| Website | https://www.scribetx.com |